Atopic Dermatitis Models

Wild Mouse 750
Wild Mouse 750
Human Xenograft Models
Cell Derived Xenograft Models
자가면역질환 모델
Rheumatoid Arthritis ModelsPsoriasis ModelsInflammatory Bowel Disease ModelsAtopic Dermatitis Models Asthma Models
대사성 질환 마우스 모델
Obesity ModelsDiabetes ModelsMASH ModelsHyperlipidemia ModelsOsteoporosis ModelsHyperuricemia Models
Humanized Immune System Models
huPBMC-NCGhuHSC-NCG-XhuHSC-NCG-hIL15huHSC-NCG
Organs or Tissue Humanized Mouse Models
Genetically Humanized Mouse Models
Wild Mouse 765
Wild Mouse 765
희귀 질환 마우스 모델
자가면역질환 모델Hemophilia A Models
신경퇴행성 질환 마우스 모델
Alzheimer’s Disease (AD) ModelsParkinson’s Disease (PD) ModelsHuntington's Disease (HD) ModelsAmyotrophic Lateral Sclerosis (ALS) ModelsTransthyretin Amyloidosis (ATTR) Models
면역-종양 마우스 모델
Human Xenograft ModelsHumanized Immune Checkpoint ModelsHumanized Immune System ModelsSpontaneous Tumor Models

Atopic Dermatitis (AD) is a chronic inflammatory skin disease characterized by Th1/Th2 lymphocyte imbalance. GemPharmatech uses Oxazolone (OXA) to induce atopic dermatitis in mice. This model can be used to test the efficacy of AD drugs.


Modeling strategy

图片5.png

Validation data

图片1.png

Compared with G2 (the OXA modeling group), the skin thickness of mouse back (upper left) and ear (upper right) was significantly decreased after dexamethasone administration, so were the clinical score (lower left), and the serum IgE levels (lower right). The results demonstrate that OXA-induced atopic dermatitis model can be used for efficacy testing. DXMS: dexamethasone

Inflammatory cells (black arrow), epidermal thickening (red arrow), hypokeratosis (green arrow), hyperkeratosis (blue arrow), keratinized pearl (yellow arrow). Bar=500 µm in the upper row. Bar=200 µm in the lower row. DXMS: dexamethasone